Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer

Central European Journal of Urology

Volumn 69, Issue 2, 2016, Pages 131-138

  Golabek, Tomasz ^a,b   Belsey, Jonathan ^c   Drewa, Tomasz ^d,e   Kołodziej, Anna ^f   Skoneczna, Iwona ^e,g   Milecki, Piotr ^h,i   Dobruch, Jakub ^j   Słojewski, Marcin ^k   Chłosta, Piotr L ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Mediqus Medical Centre   (Poland)

^c JB Medical Ltd   (United Kingdom)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e Department of Urology Nicolaus Copernicus Hospital ^*  (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ GREATER POLAND CANCER CENTRE   (Poland)

^j MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^k POMERANIAN MEDICAL UNIVERSITY   (Poland)

more..

Author keywords

Androgen deprivation therapy; Prostate cancer; Recommendations

Indexed keywords

GONADORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER SURVIVAL; EVIDENCE BASED PRACTICE; GLEASON SCORE; HUMAN; META ANALYSIS (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE ESCALATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; URINARY TRACT OBSTRUCTION;

EID: 84975126628     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2016.812     Document Type: Review

References (52)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29
2. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/nowotwory-zlosliwe-gruczolu-krokowego-c61/ accessed on 31.01, 2016
3. Climent MÁ, León-Mateos L, González Del Alba A, et al. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015; 96: 308-318
4. European Association of Urology Guidelines, 2016 edition presented at the 31st annual congress of EAU in Munich. ISBN/EAN: 978-90-79754-98-4
5. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123
6. Huggins C, Hodges C. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297
7. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. 1997; 3: 31-36
8. D’Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000; 284: 1280-1283
9. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011; 365: 107-118
10. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827
11. Laverdière J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004; 171: 1137-1140
12. Denham JW, Steigler A, Lamb DS, et al. Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850
13. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12: 451-459
14. Thompson I, Thrasher JB, Aus G, et al. Tangen CM. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. American Urological Association, https://www.auanet.org/education/guidelines/prostate-cancer.cfm, accessed on 01.02.2016
15. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 1990-1996
16. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010; 28: 1106-1111
17. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317
18. Hanks GE, Pajak TF, Porter A, et al. Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978
19. Bolla M, de Reijke TM, Van Tienhoven G, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527
20. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 1066-1073
21. Warde P, Mason M, Ding K, et al. NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011; 378: 2104-2111
22. Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol. 2012; 62: 213-219
23. Okubo M, Nakayama H, Itonaga T, et al. Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer. Oncol Lett. 2015; 10: 255-259
24. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 1998; 33: 144-151
25. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; 1: 34-45
26. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991; 67: 502-508
27. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995; 46: 220-226
28. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102: 1531-1538
29. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 339: 1036-1042
30. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet. 2000; 355: 1491-1498
31. Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J. Genitourinary Cancer Disease Site Group; Cancer Care Ontario Program in Evidence-based Care. Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006; 13: 81-93
32. National Institute for Health and Care Excellence. Final appraisal determination - Degarelix for the treatment of advanced hormone-dependent prostate cancer. Issue date: April 2014. https://www.nice.org.uk/guidance/gid-tag352/documents/prostate-cancer-advanced-hormone-dependent-degarelix-depot-fad-document2
33. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373: 737-746
34. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14: 149-158
35. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016. 387: 1163-1177
36. Vale CL, Burdett S, Rydzewska LH, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2015. 17: 243-256
37. Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65: 467-479
38. Labrie F, Bélanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005; 26: 361-379
39. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009; 6: 76-85
40. Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer. 2012; 118: 2583-2593
41. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V. Panel Members; European Society for Medical Oncology.Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013; 24: 1141-1162
42. Crawford ED, Shore ND, Moul JW, et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014; 83: 1122-1128
43. Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013; 90: 321-328
44. Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate-to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol (R Coll Radiol). 2013; 25: 190-196
45. Shore N, Crawford ED, Gittleman M, et al. Efficacy and safety of a 3-monthly depot of degarelix compared with goserelin in prostate cancer. Presented at the Society of Urologic Oncology: November 2012; Bethesda, MD, USA
46. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 2167-2172
47. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994; 12: 1868-1875
48. Cookson MS, Lowrance WT, Murad MH, Kibel AS, American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015; 193: 491-499
49. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014; 32: 3436-3448
50. Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014; 15: e404-414
51. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate Cancer Version 1.2016 at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf, accessed on 09.02.2016
52. Basch E, Loblaw DA, Oliver TK, et al. Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Onocl. 2014; 32: 3436-3448